APPLICATION OF ASCO VALUE FRAMEWORK EVALUATIONS OF NET HEALTH BENEFIT FOR ONCOLOGY DRUGS LAUNCHED IN THE UNITED STATES BETWEEN 2013 AND 2015

被引：6
|
作者：
Li, J. [1 ]
Asabere, A. [1 ]
Kelly, S. [1 ]
Cho, Y. [1 ]
Dua, D. [1 ]
Bastian, A. [1 ]
机构：
[1] GfK, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1352
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN333
引用
收藏
页码：A489 / A489
页数：1
相关论文
共 11 条
  • [1] Price migration of oncology drugs launched in the United States between 2010 and 2015
    Bastian, Alex
    Li, Jessica
    Asabere, Akwasi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework
    Delos Santos, Seanthel
    Witzke, Noah
    Gyawali, Bishal
    Arciero, Vanessa Sarah
    Rahmadian, Amanda Putri
    Everest, Louis
    Cheung, Matthew C.
    Chan, Kelvin K.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (07): : 815 - +
  • [3] Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).
    Delos Santos, Seanthel
    Witzke, Noah
    Arciero, Vanessa Sarah
    Rahmadian, Amanda Putri
    Everest, Louis
    Chan, Kelvin K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Corrected Net Health Benefit Calculations for Enzalutamide Using ASCO Value Framework Guidelines and NCCN Evidence Blocks
    Flanders, Scott
    Brown, Bruce
    Massoudi, Marjan
    Schultz, Neil
    Ramaswamy, Krishnan
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (11): : 1202 - 1202
  • [5] Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
    Cherny, Nathan I.
    de Vries, Elisabeth G. E.
    Dafni, Urania
    Garrett-Mayer, Elizabeth
    McKernin, Shannon E.
    Piccart, Martine
    Latino, Nicola J.
    Douillard, Jean-Yves
    Schnipper, Lowell E.
    Somerfield, Mark R.
    Bogaerts, Jan
    Karlis, Dimitris
    Zygoura, Panagiota
    Vervita, Katerina
    Pentheroudakis, George
    Tabernero, Josep
    Zielinski, Christoph
    Wollins, Dana S.
    Schilsky, Richard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 336 - +
  • [6] THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) NET HEALTH BENEFIT (NHB) ASSESSMENT TOOL: WHICH IMPLICATIONS FOR VALUE ASSESSMENT OF CANCER THERAPIES?
    Remuzat, C.
    Chouaid, C.
    Auquier, P.
    Borget, I
    Kornfeld, M.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A359 - A360
  • [7] PAYER MANAGEMENT AND PRICING DYNAMICS FOR NON-ONCOLOGY PHARMACY BENEFIT ORPHAN DRUGS FOR RARE DISEASES IN THE UNITED STATES LAUNCHED 2004-2014
    Dalsania, R. R.
    Leibfried, M. J.
    Richardson, S. K.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A226 - A226
  • [8] ANALYSIS OF INDICATION EXPANSIONS FOR ORPHAN-DESIGNATED, FDA-APPROVED DRUGS LAUNCHED IN THE UNITED STATES BETWEEN 2005 AND 2015
    Li, J.
    Lai, R.
    Asabere, A.
    Bastian, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A4 - A4
  • [9] APPLYING THE ASCO VALUE FRAMEWORK NET HEALTH BENEFIT SCORE (NHB) TO METASTATIC PANCREATIC CANCER (mPA) SOC THERAPIES ESTABLISHING CRITERIA FOR ASSESSING NEW NOVEL TREATMENTS
    Proach, J.
    Cromer, K.
    Dabbous, O.
    Muhsin, M.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A135 - A135
  • [10] Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit
    Desai, Nihar
    Xie, Jipan
    Wang, Yan
    Sutton, Megan B.
    Whang, John
    Fine, Jennifer T.
    Garrison, Louis P.
    [J]. CLINICAL THERAPEUTICS, 2022, 44 (01) : 52 - +
12